Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024New CM24 biomarkers data presented during the third quarter of ...

IZAR-1 will enroll biologic-naïve patients and include an evaluation of radiographic progression, while IZAR-2 will enroll ...

This also meant that the antibodies Scharffenberger generated only targeted one genetic pairing at a time. To create an ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

and while their antibody is before regulators abroad. Trailblazer-Alz6 enrolled 843 people, randomized to one of four dosing arms. The first tested the standard protocol, in which participants ...

Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 ...

One recurrent metastatic melanoma patient who was dose escalated from 210 mg ... thus enabling the combined selectivity of each CAB binding arm in the bispecific antibody. BioAtla continues to advance ...

As pharmaceutical companies embrace antibody-drug conjugates (ADCs) as a way to treat cancer, drug services providers are ...

The Company presented interim results from the TAMARACK study at the European Society for Medical Oncology (ESMO) Congress in September 2024 and expects to have mature median radiographic ...

"Either arm works the same for vaccine effectiveness, so the choice comes down to which arm folks are most comfortable with ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Arm Holdings wasn’t one of them. The 10 stocks that made the ...

Forecasts from 42 analysts give Arm a median price target of $144 per share. That implies 6% downside from its current share price of $154. Forecasts from 47 analysts give Taiwan Semiconductor a ...